Dr. Daniel Lenihan, MD
Prospective Observation of Cardiac Safety with Proteasome Inhibitor
FROM THE JOURNAL OF CLINICAL ONCOLOGY
Cardiovascular (CV) adverse events were common in patients receiving proteasome inhibitor therapy for relapsed multiple myeloma, especially with carfilzomib-based therapy, according to results from the PROTECT study.
While prior studies have shown an increased risk for CV toxicities with proteasome inhibitor therapy, detailed descriptions of the events and risk factors have been lacking. “Furthermore, there is no validated protocol to help determine which patients are at highest risk of CV toxicity during therapy, nor is there management guidance for patients who experience a [CV adverse event],” wrote Robert F. Cornell, MD, of Vanderbilt University, Nashville, Tenn., and colleagues in the Journal of Clinical Oncology.
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
By Kathleen W. Zhang, MD,a Keith E. Stockerl-Goldstein, MD,b Daniel J. Lenihan, MDa
Florida Inter-Specialty Collaborative Project to Improve Cardio-Oncology Awareness and Identify Existing Knowledge Gaps
Cancer and cardiovascular disease are 2 primary causes of morbidity and mortality in the United States (1). In addition to the physical burden of disease, there is an emotional and financial toll on patients, family members, and the health care system at large (2). The success of novel cancer therapies has resulted in significantly improved disease-free and progression-free survival for many cancers; however, many conventional and newer cancer treatments, including radiation therapy, chemotherapeutic agents, targeted therapies, and immunotherapies, are also associated with an increased risk of a number of adverse effects, including cardiovascular toxicity (3).
Journal of Clinical Medicine
Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology.
Implementing a Cardiooncology Center of Excellence Nuts and Bolts, Including Coding and Billing
Cardio-oncology is an evolving subspecialty of cardiology that deals with the acute and long-term care of cancer patients as well as cancer survivors. It has developed in concordance with the advances in oncology that have vastly increased the armamentarium of therapies for cancer patients and the subsequent cardiac toxicities that have emerged, both during therapy and sometimes decades later as cancer-related cardiac
dysfunction.1 The enormous complexity of the cancer treatments, with the myriad cardiac issues that can arise during therapy, mandate a collaboration that is diverse, knowledgeable, streamlined, cost-efficient, and, most of all, able to navigate patients through an increasingly
complicated health care system in a timely fashion.
JAMA | Original Investigation254
Ariane Macedo, MD
“Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19 A Randomized Clinical Trial”
Heart disease and breast cancer
Dr YT Singh explains that heart disease is the reason why breast cancer patients due to receive cardiotoxic therapy need a cardiovascular assessment before, during and after cancer treatment..
Perspectives on the COVID-19 pandemic impact on cardio-oncology
Re-allocation of resources during the COVID-19 pandemic has resulted in delays in care delivery to patients with cardiovascular disease and cancer. The ability of health care providers to provide optimal care in this setting has not been formally evaluated.Read more